Alnylam PharmaceuticalsALNY
ALNY
About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Employees: 2,230
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 10 (+6) [Q1 2025]
57% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 67
17% more repeat investments, than reductions
Existing positions increased: 230 | Existing positions reduced: 197
15% more call options, than puts
Call options by funds: $274M | Put options by funds: $238M
14% more capital invested
Capital invested by funds: $30B [Q4 2024] → $34.2B (+$4.18B) [Q1 2025]
5% more funds holding
Funds holding: 581 [Q4 2024] → 609 (+28) [Q1 2025]
1.24% less ownership
Funds ownership: 98.98% [Q4 2024] → 97.75% (-1.24%) [Q1 2025]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$268
13%
downside
Avg. target
$345
12%
upside
High target
$500
62%
upside
14 analyst ratings
12 positive
86%
2 neutral
14%
0 negative
0%
JP Morgan Jessica Fye | 10%upside $338 | Overweight Maintained | 12 Jun 2025 |
UBS Esther Rajavelu | 13%upside $349 | Buy Maintained | 2 May 2025 |
Chardan Capital Keay Nakae | 6%upside $325 | Buy Maintained | 2 May 2025 |
Morgan Stanley Michael Ulz | 13%downside $268 | Equal-Weight Maintained | 11 Apr 2025 |
Needham Joseph Stringer | 4%upside $320 | Buy Reiterated | 9 Apr 2025 |
Financial journalist opinion
Based on 6 articles about ALNY published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
Neutral
Business Wire
5 days ago
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and onl.
Neutral
Business Wire
2 weeks ago
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the even.
Positive
The Motley Fool
3 weeks ago
3 High-Flying Stocks That Could Soar Even More
Many investors love the "big mo." That's short for "big momentum.
Neutral
Business Wire
3 weeks ago
Alnylam Issues 2024 Corporate Responsibility Report
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This year's edition highlights the company's progress, data, and stories demonstrating its commitment to patient access,.
Neutral
Business Wire
4 weeks ago
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The results demonstrate that vutrisiran, which rapi.
Neutral
Business Wire
1 month ago
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with card.
Neutral
Business Wire
1 month ago
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after th.
Positive
Zacks Investment Research
1 month ago
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
Neutral
Seeking Alpha
1 month ago
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank of America Gena Wang – Barclays Teraesa Vitelli – Scotiabank Ellie Merle – UBS Gary Nachman – Raymond James Ritu Baral – TD Cowen Kostas Biliouris – BMO Capital Markets Luca Issi – RBC Capital Markets Paul Matteis – Stifel Mike Ulz – Morgan Stanley Operator Good morning ladies and gentlemen and welcome to the Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Charts implemented using Lightweight Charts™